Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome.
Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome in patients suffering from these conditions.
Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and will then be monitored off study treatment for an additional 4 weeks.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT01269320
|Hadassah Medical Organization, Jerusalem, Israel|
|Jerusalem, Israel, 91120|